⌕
Biodexa Pharmaceuticals · BDRX · Nasdaq
Tenet — · insufficient data
Compare
$2.00−1.98%At close
$2.00−0.04 (−1.98%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Biodexa Pharmaceuticals (BDRX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 9, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Biodexa provides R&D Update

November 9, 2026 Biodexa provides R&D Update Phase 3 Serenta trial in FAP is now two-thirds recruited Preparations advanced for Phase 1 trial of MTX240 in GIST Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “th…

● GlobeNewsWireOct 13, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

October 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on expected timing of pre-specified futility analysis and database lock Biodexa Ph…

● AccesswireSep 23, 2026 · 06:30 ET
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp

Today's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which…

● GlobeNewsWireSep 15, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company …

● GlobeNewsWireSep 11, 2026 · 16:30 ET
Interim results for the six months ended June 30, 2026

September 11, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company de…

GlobeNewsWire · Nov 9, 2026

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

ANT24−6.6%
NVDA7−2.3%
FOX6−2.9%
AMD3−6.0%

Article counts from the last market-wide feed page, across every symbol we track and not just BDRX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.